Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Voir en d'autres langues

Nouvelles

###

142,072 COMPANY PROFILE VIEWS

  • This Page Viewed: (7 derniers jours: 30) (Last 30 Days: 104) (Since Published: 10931) 

Company Data

    Fax
  • (03) 9853 5134 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

More News Results

  • 2025/08/05: Application for quotation of securities - PTX*
  • 2025/07/31: Proposed issue of securities - PTX*
  • 2025/07/31: Prescient successfully completes $3 million Placement*
  • 2025/07/30: June 2025 Quarterly Update and Appendix 4C*
  • 2025/07/29: Prescient announces results of SPP & Launches Placement*
  • 2025/07/29: Trading Halt*
  • 2025/07/22: Prescient Therapeutics - Extension of Share Purchase Plan*
  • 2025/07/16: PTX Opens First U.S. Site for PTX-100 Phase 2a Trial*
  • 2025/07/15: Update - Proposed issue of securities - PTX*
  • 2025/07/15: Prescient Therapeutics Extends Share Purchase Plan*
*refer to company website